National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The trial consists of a series of parallel multi-centre single arm phase II trial arms, each
testing an experimental targeted drug in a population stratified by multiple pre-specified
actionable target putative biomarkers. The primary objective is to evaluate whether there is
a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive
design is adopted to achieve this objective and statistical details are given in the
Protocol.
Phase:
Phase 2
Details
Lead Sponsor:
University of Birmingham
Collaborators:
AstraZeneca Cancer Research UK Experimental Cancer Medicine Centre Network Experimental Cancer Medicine Centres Mirati Therapeutics Inc. Pfizer